Merck moves into mRNA space with Moderna alliance
This article was originally published in Scrip
Moderna Therapeutics, the subject of the largest ever biotech private equity fundraising of $450m earlier this month (scripintelligence.com, 6 January 2015), has signed a license and collaboration agreement with Merck & Co for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).
You may also be interested in...
Moderna Therapeutics LLC will go public someday, CEO Stephane Bancel says, but not until the company has human proof-of-concept data for multiple messenger RNA (mRNA) therapeutics – a milestone that Moderna expects to reach with its $474m in new equity financing.
The companies will work together to develop personalized cancer vaccines against several tumor types, including an effort to pair a personalized vaccine with Keytruda.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.